Cardiovascular toxic effects of targeted cancer therapy

Japanese Journal of Clinical Oncology
Kazuko TajiriIkuo Sekine

Abstract

Over the past decade, there has been a major shift in chemotherapy from non-specific cytotoxic drugs to molecular targeted drug therapies. As more molecular targeted therapies are developed, new types of cardiovascular toxicities induced by targeted therapies are a growing problem. Cardiotoxicity induced by the human epidermal growth factor receptor-2 inhibitor trastuzumab manifests as decreased left ventricular ejection fraction. In contrast to anthracycline treatment, most cardiac events occur during trastuzumab treatment, but are reversed quickly when treatment is interrupted and cardiac intervention is established. Vascular endothelial growth factor pathway inhibitors decrease vascular tone, leading to hypertension. After drug initiation, the early detection and aggressive pharmacological management of hypertension are necessary to avoid severe complications. Cardiovascular safety is an emerging challenge in patients treated with newer generations of BCR-ABL inhibitors. Although rare, dasatinib-induced pulmonary hypertension is potentially fatal. Vascular events including cardiac and cerebral ischemic events and peripheral arterial occlusive disease have emerged as a new type of toxicity in patients treated with ponatinib a...Continue Reading

References

Nov 23, 1995·Nature·D Meyer, C Birchmeier
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew SeidmanDeborah Keefe
May 2, 2002·Nature Medicine·Steven A CroneKuo-Fee Lee
Jun 20, 2002·Proceedings of the National Academy of Sciences of the United States of America·Cemil OzcelikAlistair N Garratt
Dec 17, 2004·Pharmacological Reviews·Ann HoebenErnst A De Bruijn
Oct 21, 2005·The New England Journal of Medicine·Martine J Piccart-GebhartUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Oct 21, 2005·The New England Journal of Medicine·Edward H RomondNorman Wolmark
Dec 21, 2005·Journal of Cellular and Molecular Medicine·Anne Marie ByrneJ H Harmey
Sep 19, 2008·The New England Journal of Medicine·Ralph L Nachman, Shahin Rafii
Nov 20, 2008·JAMA : the Journal of the American Medical Association·Shobha Rani NalluriShenhong Wu
Mar 17, 2009·Best Practice & Research. Clinical Haematology·Francesca EliceFrederick R Rickles
Mar 31, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Toni K ChoueiriJoaquim Bellmunt
Mar 31, 2010·Journal of the National Cancer Institute·Michael L MaitlandUNKNOWN Cardiovascular Toxicities Panel, Convened by the Angiogenesis Task Force of the National Cancer Institute Investigational Dr
Apr 30, 2011·Journal of the National Cancer Institute·Brian I RiniRobert J Motzer
Oct 14, 2011·The New England Journal of Medicine·Dennis SlamonUNKNOWN Breast Cancer International Research Group
Mar 28, 2012·Circulation·David MontaniMarc Humbert
Jun 19, 2012·Journal of the American College of Cardiology·Michael Simons, Anne Eichmann
Aug 4, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S GeorgeG D Demetri
Nov 20, 2012·Journal of the American College of Cardiology·Jersey ChenCary P Gross
Oct 16, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mariana Chavez-MacGregorSharon H Giordano
Mar 4, 2014·Journal of the American Heart Association·Ghideon EzazJersey Chen
Jun 11, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Evandro de AzambujaThomas M Suter
Jan 2, 2015·Breast Cancer Research and Treatment·Anthony F YuRichard M Steingart
Jan 8, 2015·The New England Journal of Medicine·Sara M TolaneyEric P Winer

❮ Previous
Next ❯

Citations

Nov 2, 2018·Recent Patents on Anti-cancer Drug Discovery·Maricruz Anaya-RuizMartín Pérez-Santos
Oct 19, 2017·Japanese Journal of Clinical Oncology·Kazuko TajiriIkuo Sekine
Jan 6, 2018·Japanese Journal of Clinical Oncology·Hideo Kunitoh
Nov 29, 2020·Molecular and Cellular Biochemistry·Huiling ZhouHaidan Liu
Feb 24, 2021·Expert Review of Clinical Pharmacology·Zeng WangPeihua Luo
Aug 29, 2021·Cardio-Oncology·Shunsuke MarutaMasaki Ieda

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.

Related Papers

Progress in Cardiovascular Diseases
Giuseppe CuriglianoAron Goldhirsch
Current Treatment Options in Cardiovascular Medicine
Rongras Damrongwatanasuk, Michael G Fradley
© 2022 Meta ULC. All rights reserved